News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Neuren Pharmaceuticals Limited to Move to Phase 2 Trial of NNZ-2566 on TBI
September 20, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Sydney, Sep 20, 2007 -- Neuren Pharmaceuticals has completed cohorts 1 and 2 of its Phase 1b trial to test the safety, tolerability and pharmacokinetic action of NNZ-2566 as a compound to treat traumatic brain injury (TBI).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Australia
MORE ON THIS TOPIC
Pipeline
Pharma Pipeline Stalls for First Time in Decades: Citeline
April 6, 2026
·
2 min read
·
Tristan Manalac
Insights
Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death”
April 6, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Vaccines
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment
April 2, 2026
·
2 min read
·
Nick Paul Taylor
Insights
The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment
April 2, 2026
·
1 min read
·
Jennifer C. Smith-Parker
